Abstract:Purpose: The purpose of this study is to evaluate the therapeutic potential of neural stem cells expressing PTEN-L (a variant of the tumor suppressor PTEN that can transfer between cells) in preclinical glioblastoma models. Experimental procedures: Human neural stem cells derived by direct reprogramming of peripheral blood erythroblasts were used. Using lentiviral transduction, these were engineered for doxycycline-inducible expression of a modified version of PTEN-L with optimized expression and enhanced cell-to-cell transfer properties. Expression of PTEN-L was assayed by Western blot analysis. These engineered neural stem cells were evaluated in an orthotopic mouse xenograft model in which human glioblastoma cells show extensive invasion into the uninjected hemisphere. Neural stem cells and glioblastoma cells were co-injected and mice were then randomized to chow with or without doxycycline. Mice were evaluated for overall survival and for invasion of glioblastoma cells into the uninjected hemisphere. Results: When injected intracerebrally into immunocompromised mice, peripheral blood-derived neural stem cells persisted for over four months and showed an ability to spontaneously migrate to sites distant from the injection site. When co-injected with human glioblastoma cells from patients, the neural stem cells co-migrated with glioblastoma cells along the corpus callosum and to distant sites. Peripheral blood-derived neural stem cells transduced with lentiviral vectors for doxycycline-inducible PTEN-L efficiently secreted PTEN-L. In the orthotopic mouse xenograft glioblastoma model, expression of PTEN-L by neural stem cells did not significantly improve survival in mice (log rank P = 0.5) but did significantly repress glioblastoma cell invasion into the uninjected hemisphere (two-tailed t-test P = 0.02). Conclusions. Peripheral blood-derived neural stem cells show good persistence and migrate with human glioblastoma cells in vivo. They can be engineered to efficiently secret functional PTEN-L. Peripheral blood-derived neural stem cells expressing PTEN-L do not increase survival in the one patient model tested but do repress invasion. This initial evidence for bioactivity supports further studies evaluating the ability of neural stem cells expressing PTEN-L to sensitize glioblastoma to therapeutics for which PTEN loss has been implicated in resistance. Citation Format: Ian A. Lorimer, Margarita Lui, Sylvie J. Lavictoire, Josee Coulombe. Neural stem cells expressing PTEN-L suppress glioblastoma invasion in vivo [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1) nr A020.

Abstract A020: Neural stem cells expressing PTEN-L suppress glioblastoma invasion in vivo